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Synovial tissues of patients with rheumatoid arthritis (RA) include factors regulating bone resorption, such as receptor activator
NF-κB ligand (RANKL), TNF-α, IL-6, IL-17, and IFN-γ. However, in addition to these cytokines, other factors expressed in
synovial tissues may play a role in regulating bone resorption. In 2009, we demonstrated that novel peptides from T-cell
leukemia translocation-associated gene (TCTA) protein expressed in synovial tissues from patients with RA inhibit human
osteoclastogenesis, preventing cellular fusion via the interaction between TCTA protein and a putative counterpart molecule.
Only a few studies on the role of TCTA protein have been reported. Genomic Southern blots demonstrated a reduced TCTA signal
in three of four small cell lung cancer cell lines, suggesting the loss of one of the two copies of the gene. In the current paper, we
reviewed the roles of TCTA protein in lung cancer cell lines and human osteoclastogenesis.
1.Introduction
Synovial tissues of patients with rheumatoid arthritis (RA)
include factors regulating bone resorption by expressing cy-
tokines such as RANKL, TNFα, IL-6, IL-17, and IFN-γ [1–
10].Inaddition tothesecytokines,however,otherfactorsex-
pressed in synovial tissues may play a role in resorbing bone.
To identify novel peptides or proteins expressed in synovial
tissues of patients with RA that regulate human osteoclasto-
genesis, we puriﬁed proteins from synovial tissues of patients
with RA, using gel ﬁltration chromatography, reverse-aspect
HPLC, and mass spectrometry. We ﬁnally demonstrated
that a peptide derived from the extracellular domain of T-
cell leukemia translocation-associated gene (TCTA) protein
inhibited both RANKL-induced human osteoclastogenesis
and pit formation of mature human osteoclasts [11, 12].
2 .T h eR o l eo fT C T AP r o t e ino nH um a nS m a ll
CellLungCancerCellLines
In 1995, Aplan et al. cloned and characterized a novel gene at
the site of a t(1;3)(p34;p21) translocation breakpoint in
T-cell acute lymphoblastic leukemia (ALL), designating
t h i sg e n ea sT C T A[ 13]. TCTA is also reported as T-cell
leukemia translocation-altered gene. TCTA mRNA is ex-
pressed ubiquitously in normal tissues, with the highest
levels of expression in the kidney. TCTA has been conserved
throughout evolution in organisms ranging from Drosophila
to humans. A short open reading frame encodes a protein
of 103 amino acid residues, Mr 11,300, without strong ho-
mology to any previously reported proteins.
Aplan et al. reported that a preliminary survey of 44
cases of childhood ALL (9 T-cell- and 35 B-cell-) precursors
did not reveal any gross structural alterations of TCTA by
Southern blot [13]. Additionally, they sequenced the TCTA
gene from the translocated allele in the t(l;3) translocation
and found no mutations in the open reading frame [13];
however, it remains possible that more complete studies of
a larger series of T-cell ALL patients may reveal a more direct
role for TCTA dysregulation in T-cell ALL [13].
Ofnote,genomicSouthernblotsdemonstratedareduced
TCTA signal in three of four small cell lung cancer cell
lines, suggesting the loss of one of the two copies of the
gene [13]. On the other hand, in 2005, it has been reported
that TCTA interacts with SMA- and MAD-related protein 42 Journal of Biomedicine and Biotechnology
(SMAD4) in a proteome-scale map of the human protein-
protein interaction network (Supplementary Table S2 of
[14]); however, the function of TCTA has not been clariﬁed.
3. Osteoclast
3.1. Structure and Function of Osteoclasts. Osteoclasts are
unique multinucleated cells whose specialized function is to
resorb calciﬁed tissues [7]. On the surface of bone, os-
teoclasts develop a specialized adhesion structure, the “pod-
osome”, which subsequently undergoes reorganization into
sealing zones [15]. These ring-like adhesion structures, that
is, actin rings, seal osteoclasts to the surface of bone. In
the sealed resorption lacuna, localized acidiﬁcation is driven
by carbonic anhydrase II and vacuolar H(+)-ATPase in
osteoclasts; carbonic anhydrase II produces protons and
vacuolar H(+)-ATPase transfers them into the lacuna. In
acidiﬁed lacuna, cathepsin-K and matrix metalloproteinase-
9 (MMP-9) are released from osteoclasts to degrade calciﬁed
tissues [16].
Osteoclasts express unique celladhesion structurescalled
podosomes, which contain actin ﬁlaments. Podosomes are
organized diﬀerently depending on the activity of the osteo-
clast; in bone-resorbing osteoclasts, podosomes form the
actin ring, representing a gasket-like structure, necessary for
bone resorption, and in motile osteoclasts, podosomes are
organized into lamellipodia (Latin lamella, a thin leaf; Greek
pous, foot), the structure responsible for cell movement.
Thus,thepresenceofactinringsandlamellipodiaismutually
exclusive [17]. In 2004, Sarrazin et al. showed, using mature
human osteoclasts extracted from the femurs and tibias of
human fetuses, that osteoclasts have two subtypes of EP
receptors, EP3 and EP4, that mediate diﬀerent actions of
PGE2 on these cells; activation of EP4 receptors inhibits actin
ring formation and activation of EP3 receptors increases the
number of lamellipodia [17]. Thus, PGE2 directly inhibits
bone resorption by human osteoclasts.
The cooperation of osteoclasts and osteoblasts is critical
to maintain skeletal integrity in normal bones. After bone re-
sorption by osteoclasts on normal bone tissues, osteoblasts
subsequently rebuild bone in the lacunae resorbed by os-
teoclasts; this mechanism is called “bone remodeling”. When
the activity or number of osteoclasts is elevated compared
with osteoblasts, the bone becomes fragile, that is, “osteo-
porotic”. In addition, bone remodeling is disrupted in all
bone diseases associated with changes in bone mass. Thus,
bone remodeling is essential to retain both the structure and
strength of normal bone.
3.2. Origin of Osteoclasts. The origin of osteoclasts was un-
clear until the late 1980s. In 1988, Takahashi et al. established
a coculture system using mouse spleen cells and osteoblasts
to induce osteoclastogenesis in vitro, demonstrating that the
originofosteoclastsishematopoieticcellsandthatosteoblas-
tic cells are required for the diﬀerentiation of osteoclast pro-
genitors in splenic tissues into multinucleated osteoclasts
[18]. The precursor of osteoclasts was then revealed to
be colony-forming unit-macrophage (CFU-M) or CFU-
granulocyte/macrophage (CFU-GM) in bone marrow or
spleen in mice. In 1990, Udagawa et al. demonstrated that
osteoclastsareformedfrommurinemacrophages[19].From
these ﬁndings, Suda et al. hypothesized that bone mar-
row hemopoietic cells diﬀerentiate into osteoclasts through
the stimulation of “osteoclast-diﬀerentiation factor (ODF)”
expressed on osteoblasts [20].
Finally, ODF, now termed RANKL, which induces osteo-
clastogenesis frommonocytes or macrophages, was indepen-
dently cloned by three groups in 1997 [21]. RANKL is a
member of the TNF superfamily of cytokines. The protein
constructs a trimeric complex to bind its receptor, receptor
activator NF-κB (RANK) [22]. A decoy receptor is also
cloned,whichisdesignatedas“osteoprotegerin(OPG)”[21].
In 2000-2001, we and other groups showed that T cells
expressing RANKL induce osteoclastogenesis [1, 6, 23]; in
particular, we demonstrated osteoclastogenesis using human
cells [6] ,w h e r e a so t h e r su s e dm u r i n ec e l l s[ 1, 23]. In addi-
tion, in 2009, we reported that, in human osteoclastogenesis
inducedbyRANKL,T-cellleukemiatranslocation-associated
gene (TCTA) protein is required for cellular fusion [11].
3.3. Development of Culture Systems to Form Osteoclasts In
Vitro. Culture systems were developed to form osteoclasts in
vitro in 1981–1988. In 1981, Testa et al. ﬁrst succeeded in
forming osteoclast-like multinucleated cells from feline mar-
row cells in long-term Dexter cultures [24]. In 1984, using
this feline marrow culture system, Ibbotson et al. showed
thattheformationofosteoclast-likecellsisgreatlystimulated
by osteotropic hormones, such as 1,25(OH)2D3,P T H ,a n d
prostaglandin E2 (PGE2)[ 25]. In 1987, MacDonald et al.
reported the formation of multinucleated cells that respond
to osteotropic hormones in long-term human bone marrow
cultures[26].In1988,Takahashietal.andin1989,Hattersley
and Chambers used marrow cells of mice to examine
osteoclast-like cell formation from their progenitor cells
[27, 28]. Moreover, in 1988, Takahashi et al. established an
innovative co-culture system using mouse spleen cells and
osteoblasts to induce osteoclastogenesis in vitro [18]. Thus,
since 1981, studies using osteoclastogenesis in vitro have
been developed, and PGE2 was shown to upregulate murine
osteoclastogenesis using the marrow culture system in vitro.
3.4. Role of Osteoclasts in the Pathogenesis of RA. Osteoclasts
also play an important role in the pathogenesis of RA. Since
1984, it has been reported that in bone destruction of RA,
many activated osteoclasts are detected on the surface of
eroded bone in the interface with synovial tissues [29]. In
addition, we have demonstrated that osteoclasts are detected
in synovial tissues as well as eroded bone from patients with
RA [4]. We have also reported that the number of precursor
cells of osteoclasts increases in bone marrow adjacent to
joints with arthritis [30]. Moreover, the amount of cytokine
that induces osteoclastogenesis, such as IL-1, TNF-α,a n dI L -
6, is elevated in synovial tissues of patients with RA, while
the amount of cytokine that inhibit osteoclastogenesis, such
as IL-4 and IL-10, is decreased [30–32]. Thus, patients withJournal of Biomedicine and Biotechnology 3
RA are likely to suﬀer from joint destruction as well as
systemic osteoporosis, in which the number of osteoclasts
increases, suggesting that osteoclasts play a critical role in the
pathogenesis of RA.
3.5. Geranylgeranylacetone Inhibits the Formation and Func-
tion of Human Osteoclasts. The antiulcer drug geranylgeran-
ylacetone (GGA), known as Teprenone, is frequently used
with NSAIDs in Japan. In 2005, we demonstrated that GGA
inhibits the formation and function of human osteoclasts
and prevents bone loss in tail-suspended rats and ovariec-
tomized rats [33]. Vitamin K is also used to protect against
osteoporosis. It has been reported that the inhibitory eﬀect
of vitamin K2 (menatetrenone) on bone resorption may be
related to its side chain. GGA has almost the same chemical
structure as the side chain of menatetrenone.
We hypothesized that GGA also has an inhibitory eﬀect
on osteoclastogenesis both in vitro and in vivo. GGA in phar-
macological concentrations directly inhibited osteoclastoge-
nesis from human monocytes induced by soluble RANKL.
In addition, GGA induced the degradation of actin rings in
mature osteoclasts, which was reversed by adding geranyl-
geranylpyrophosphatase. Moreover, GGA increased the bone
mineral density of the total femur, proximal metaphysis,
and diaphysis of femur in ovariectomized rats. GGA also
prevented bone loss induced by hindlimb unloading in tail-
suspended rats. These results indicate that GGA prevents
bone loss by maintaining a positive balance of bone turnover
through suppression of both the formation and activity
of osteoclasts. In addition, in 2009, we also reported that
GGA induces cell death in ﬁbroblast-like synoviocytes from
patients with rheumatoid arthritis [34]. Thus, GGA could
be used to prevent and improve osteoporosis, especially in
patients with RA.
4. Role of TCTA Proteinin
HumanOsteoclastogenesis
4.1. Hypothesis. Synovial tissues of patients with RA include
factors regulating bone resorption by expressing cytokines
such as RANKL, TNFα, IL-6, IL-17, and IFNγ as described
in Introduction. In addition to these cytokines, however,
other factors expressed in synovial tissues may play a role
in resorbing bone. We hypothesized that a novel factor in
synovial tissues of patients with RA regulates osteoclasto-
genesis. To test this hypothesis, we tried to identify novel
peptides or proteins expressed in synovial tissues of patients
with RA that regulate human osteoclastogenesis since 1996.
We puriﬁed proteins from synovial tissues of patients
with RA, using gel ﬁltration chromatography, reverse-aspect
HPLC, and mass spectrometry. We ﬁnally demonstrated
that a peptide derived from the extracellular domain of T-
cell leukemia translocation-associated gene (TCTA) protein
inhibited both RANKL-induced human osteoclastogenesis
and pit formation of mature human osteoclasts [11, 12, 35,
36]. We would like to present our ﬁndings as follows.
4.2. Puriﬁcation of Proteins from Synovial Tissues of Patients
with RA. Sixty-ﬁve grams of synovial tissues were obtained
from5patients withRAattotalkneereplacement.Thecrude
extract was obtained by homogenization of the synovial
tissues. NH3Ac buﬀer was added to the freeze-dried crude
extract. The supernatant was then applied to the column
equilibrated with NH3Ac buﬀer and divided into two frac-
tions, low molecular weight (MW) and high MW by ﬁrst
gel ﬁltration chromatography. The low MW fraction was
further applied to the column equilibrated with PBS by
the second gel ﬁltration chromatography. Proteins were
eluted and protein concentration (A280) was monitored
by UV absorption. Each fraction was added to the culture
for human osteoclastogenesis to evaluate the activity on
the osteoclastogenesis. Two fractions showed the inhibitory
activity of osteoclastogenesis. These fractions were then sub-
jected to ion-exchange chromatography. The “ﬂow through”
from the column showed the inhibitory activity on the
osteoclastogenesis. The “ﬂow through” was then applied to
second gel ﬁltration chromatography. Ten fractions from
gel ﬁltration chromatography showed the inhibitory activity
on osteoclastogenesis. Thus, these fractions were applied to
reverse-aspect HPLC. Thirty fractions were obtained by the
reverse-aspect HPLC.
After each fraction obtained by reverse-aspect HPLC was
concentrated, amino acid sequences were determined using
a protein sequencer. Amino acid sequences (3–5mers) were
determined in 8 fractions. In addition, we tried to determine
thesequenceofeachfractionbymassspectrometry;however,
the sequences were not determined, although the total
molecular weight of each peptide was speculated to be less
than 1000Da. Thus, we synthesized 8 peptides according to
the sequences determined using the protein sequencer and
evaluated the eﬀect of each peptide on human osteoclastoge-
nesis in vitro.
4.3. A Small Peptide Including GQN Inhibits Human
Osteoclastogenesis. We ﬁnally revealed that the amino acid
sequence of Glycine-Glutamine-Asparagine (Gly-Gln-Asn;
GQN) alone in 8 synthesized peptides showed inhibitory
activity in human osteoclastogenesis; GQN dose-depend-
ently inhibited human osteoclastogenesis from peripheral
monocytes by RANKL (IC50: around 30μM) [11].
When searching for proteins that include GQN using
FASTA search, we found only 2 proteins in human proteins,
CDW52 antigen (CAMPATH-1 antigen) and TCTA. In the
FASTA search, it was possible to identify 3 mer peptides,
but we did not ﬁnd any other human proteins. Using
“PeptideCutter”, by which it is possible to predict the site
cleaved by enzymes in peptides, we synthesized 4 peptides
from a sequence of CDW52 antigen and one peptide from a
sequence of TCTA protein, which included GQN.Ap e p t i d e
from TCTA protein showed inhibitory activity on human
osteoclastogenesis, but not peptides from CDW52 antigens.
4.4. Peptide A from TCTA Strongly Inhibits Human, but Not
Mouse, Osteoclastogenesis. We then synthesized another 2
peptides,GQNGSTPDGSTHFPSWEMAANEPLKTHREand4 Journal of Biomedicine and Biotechnology
GQNGSTPDGSTHFPSWEMAAN, using “PeptideCutter”,
shownas“peptideA”(MW3182.4)and“peptideA2”,respec-
tively, from a sequence of TCTA gene protein (Figure 1).
Osteoclastogenesis was more potently inhibited by these
peptides than by GQN or GQNGST. Peptide A most strongly
inhibited osteoclastogenesis; IC50 level was around 1.6μM.
Osteoclastogenesis induced by soluble RANKL (sRANKL)
was not inhibited by adding 1.6μM of a scrambled pep-
tide, SPFTGTKGSWNETAHPDHGNEERQAPMSL (MW,
3182.4), randomly designed from the sequence of peptide
A. We ﬁnally synthesized 3 more peptides from a se-
quence of TCTA protein, also using “PeptideCutter”: “pep-
tide B”: GQNGSTPDGSTHF, “peptide C”: PGLGGQNGS-
TPDGSTHF, and “peptide D”: GFYGNTVTGLYHRPG-
LGGQNGSTPDGSTHFPSWEMAANEPLKTHRE, which is
the whole of the human extracellular domain (Figure 1).
Sequences of both peptide B and peptide C are included
in a human/mouse identical sequence of TCTA protein
(Figure 1).
Both peptide B and peptide C showed a weak inhibitory
eﬀect on human osteoclastogenesis from human peripheral
monocytes. Peptide D did not show inhibitory activity. On
theotherhand,wealsoexaminedtheeﬀectsofthesepeptides
on mouse osteoclastogenesis; however, in contrast to our
expectation, peptides B and C, which are included in the
mouse sequence, did not inhibit ddY mouse osteoclastoge-
nesis from mouse bone marrow cells stimulated by sRANKL
and M-CSF. Peptides A and D did not show the inhibitory
eﬀectsonmousecellsasweexpected.PeptideAdidnotshow
cytotoxicity on human monocytes or cell proliferation on
human monocytes [11].
4.5. Peptide A Failed to Inhibit the Expression of Protein and
mRNA of NFATc1, and mRNA of Cathepsin K. We then
examined the eﬀect of peptide A on the expression of both
protein and mRNA of NFATc1, a key regulator of osteoclas-
togenesis under the signals of RANK-RANKL, in osteoclasts.
Peptide A appeared to weakly inhibit the expression of pro-
teinofNFATc1inosteoclastsinimmunohistologicalstaining
for NFATc1. Peptide A (0.8–3.2μM) also weakly, but not
signiﬁcantly, inhibited the expression of mRNA of NFATc1
in osteoclasts. In addition, peptide A did not inhibit the
expression of mRNA of cathepsin K using the scrambled
peptide as a control [11].
4.6. Peptide A Inhibits Pit Formation of Mature Human
Osteoclasts in the Culture of 3 Days, but Not 24h. We then ex-
amined the eﬀect of peptide A on pit formation of mature
human osteoclasts on Osteologic. Mature osteoclasts formed
from monocytes in culture with RANKL and M-CSF for
14 days were removed from plates. The mature osteoclasts
then cultured on Osteologic discs with peptide A or a
scrambled peptide in the presence of RANKL and M-CSF
for 24h or 3 days. Peptide A as well as a scrambled peptide
did not inhibit pit formation for 24h. However, peptide A
signiﬁcantly inhibited pit formation in the culture of 3 days,
although a scrambled peptide did not inhibit pit formation
at all. Thus, peptide A showed inhibitory activity on mature
human osteoclasts in the culture of 3 days, but not 24h [11].
4.7. Peptide A Suppresses the Formation of Large Osteoclasts in
the Culture of Mature Human Osteoclasts. We then investi-
gated the eﬀects of peptide A on mature osteoclasts cultured
with sRANKL and M-CSF for 3 days. In the control well with
sRANKL alone in the absence of peptide A, larger osteoclasts
were formed than osteoclasts cultured with sRANKL and
peptide A. Huge osteoclasts were detected in the control
well alone, but not in the well cultured with peptide A.
Osteoclasts in the well cultured with peptide A showed usual
size. The number of huge osteoclasts in the control well
cultured without peptide A was signiﬁcantly higher than in
the well cultured with peptide A. Thus, we hypothesized that
TCTA plays a role in the fusion of monocytes/macrophages,
preosteoblasts, and osteoclasts [11].
4.8. Polyclonal Antibodies against TCTA Inhibit Both Human
Osteoclastogenesis from Monocytes and Fusion of Mature
Osteoclasts. We constructed indirect competitive enzyme-
linked immunosorbent assay (ELISA) using 2 polyclonal
antibodies against TCTA protein. Standard curves showed
speciﬁcity and high aﬃnity of the antibodies against TCTA
protein. To investigate our hypothesis further, we cultured
monocytes with M-CSF and sRANKL in the presence of the
polyclonal antibody, #1 or #2, both of which signiﬁcantly
inhibited human osteoclastogenesis, reducing the size of
osteoclasts. In addition, polyclonal antibody #2 inhibited the
fusion of mature osteoclasts [11].
4.9. TCTA Protein Is Immunohistologically Detected on
Human Osteoclasts and Macrophages. Using antibody no. 1,
TCTA protein was immunohistologically detected on human
osteoclasts induced by sRANKL and M-CSF. TCTA protein
was detected in the central area of cells or in the peripheral
area of cells. TCTA protein stained in the peripheral area of
cells was observed in both a preosteoclast with 2 nuclei and
an osteoclast with 4 nuclei, using ﬂuorescent microscopy.
TCTA protein also detected human macrophages cultured
with M-CSF [11].
4.10. Other Findings on Peptide A. Peptide A as well as a
scrambled peptide failed to disrupt the structure of actin
rings of mature osteoclasts in the culture of 24h and 3
days. The amount of TCTA mRNA was signiﬁcantly lower in
human osteoclasts induced by sRANKL and M-CSF than in
human macrophages cultured with M-CSF alone. Peptide A
orthescrambledpeptidedidnotreducetheamountofTCTA
mRNA in osteoclasts. TCTA mRNA was detected in human
osteoclasts, monocytes, ﬁbroblast-like synoviocytes, T cells,
and PBMC by RT-PCR. TCTA protein was immunohis-
tologically detected in cultured ﬁbroblast-like synoviocytes
using polyclonal anti-TCTA antibodies #1. TCTA protein
was also immunohistologically detected in synovial tissues
using polyclonal anti-TCTA antibodies #1. TCTA protein-
positive cells were detected in synovial lining cells, but not in
lymphoid follicular with many lymphocytes. TCTA proteinJournal of Biomedicine and Biotechnology 5
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Figure 1: Structure of TCTA and sequences of peptides. Structure of TCTA showing both intra-cellular (white bar) and extra-cellular
(meshed bar) domains. Black bar shows the human/mouse identical sequence in the extra-cellular domain.
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Figure 2: Possible mechanism of human osteoclastogenesis by
peptide A and antibodies against TCTA protein. (Structure of
TCTA is derived from SOSUI; http://bp.nuap.nagoya-u.ac.jp/sosui/
sosui submit.html). TCTA protein plays an important role in
cellular fusion in human osteoclastogenesis from monocytes and
mature osteoclasts. Both peptide A and antibodies block the in-
teraction between TCTA protein and a putative counterpart of
TCTA protein.Modiﬁed from the ﬁgure in [11].
was signiﬁcantly detected in human monocytes by ﬂow
cytometry using polyclonal anti-TCTA antibody no. 1 [11].
5.ANovelHypothesisin
HumanOsteoclastogenesis
We demonstrated that a novel peptide derived from the
amino acid sequence of the extracellular domain of TCTA
protein inhibited not only RANKL-induced human osteo-
clastogenesis from monocytes but also fusion of activated
mature human osteoclasts [11]. In the culture of mature os-
teoclasts,peptideAsuppressedtheformationoflargemature
osteoclasts after 3 days in the presence of sRANKL. In
addition, although peptide A inhibited human osteoclas-
togenesis from monocytes with sRANKL, peptide A did
not show signiﬁcant inhibition of both protein and mRNA
of NFATc1. The inhibitory eﬀects of peptide A were not
diﬀerent among early, middle, and late phases of culture. In
addition, the structure of actin rings of mature osteoclasts
was not disrupted by peptide A. Thus, taken together, our
ﬁndings suggest that the extracellular domain of TCTA
may play a role in the fusion of osteoclast precursors
and mature osteoclasts and that peptide A may block the
interaction of TCTA and a putative counterpart of TCTA
(Figure 2). Supporting our putative mechanism, Saginario
et al. reported that, because the soluble extracellular domain
of macrophage fusion receptor (MFR) prevents the fusion of
macrophages in vitro, MFR belongs to the fusion machinery
of macrophages [37].
Several studies have reported that peptides inhibit osteo-
clastogenesis [38–40]. Jimi et al. reported that, using a cell-
permeable peptide inhibitor of the I-κB-kinase complex,
the peptide inhibits RANKL-stimulated NF-κBa c t i v a t i o n
and osteoclastogenesis both in vitro and in vivo. They also
showed that this peptide signiﬁcantly reduces the severity
of collagen-induced arthritis in mice by reducing levels of
TNFα and IL-1β, abrogating joint swelling and reducing the
destruction of bone and cartilage [40]. They used 20μMo f
peptides to inhibit RANKL-induced mice osteoclastogenesis,
whereas our peptide A inhibited RANKL-induced human
osteoclastogenesisat1.6μMofIC50.Thus,ourpeptidemore
eﬀectively inhibits osteoclastogenesis, although the diﬀerent
eﬃcacy of the peptides may be derived from the diﬀerent
species used, humans and mice.
The reasons why peptides B and C, included in the
mouse sequence, did not inhibit the osteoclastogenesis from
mouse bone marrow cells remain unclear. We used only 3
peptides, peptide B, peptide C, and mouse “peptide A”, in
the culture of mouse cells. The other peptides, including
GQN, may inhibit mouse osteoclastogenesis. On the other
hand, even if TCTA protein plays a role in fusion as discussed
above, TCTA protein in mice may be less important than
theothermoleculesforfusion, suchas,dendritic cell-speciﬁc
transmembraneprotein(DC-STAMP)[41],CD9[42],CD47
[9, 43], macrophage fusion protein (MFR) [37, 43, 44], E-
cadherin [45–47], meltrin-α (ADAM12) [48], or CD44 [49].
Theseﬁndingsalsounderlinethediﬀerenceofdiﬀerentiation6 Journal of Biomedicine and Biotechnology
of osteoclasts between human and mice, supporting the
importance of the term, “human osteoclastology” [50].
In conclusion, we demonstrated that peptide A and pol-
yclonal antibody against TCTA protein inhibited not only
human osteoclastogenesis from monocytes but also the fur-
ther maturation of mature human osteoclasts in vitro [11].
Our ﬁndings suggest that TCTA protein plays an important
role in cellular fusion in human osteoclastogenesis from
monocytes and mature osteoclasts. Thus, peptide A may
show the same inhibitory function in vivo,o ﬀering an eﬀec-
tive therapeutic approach for inhibiting bone resorption.
6.Costimulation of TCTA on Human Small Cell
LungCancer andHumanOsteoclastogenesis
Metastatic bone tumors occur at particularly high rates in
cancers of the breast, prostate, lung, and kidney. Many pa-
tients with lung cancer are in advanced stages of the disease
at the time of diagnosis. The 5-year survival rate for patients
with lung cancer is 10% to 20%, indicating a poor prognosis.
In addition, it is reported that bone metastasis from lung
cancer occurs in 14% to 40% of patients [51]. The same side
of the ribs and spine are the most common. For lung can-
cer bone metastases, surgical treatment, radiation therapy,
chemotherapy, and the biological treatment are performed;
however, the eﬀects are not suﬃcient.
It was reported that TCTA protein may regulate the tu-
morigenesis of small cell lung cancer, although the mecha-
nism remains elucidative [13]. We have demonstrated that
TCTA protein induces human osteoclastogenesis by up-
regulating cellular fusion. Thus, it may be possible to treat
lung cancer bone metastases by regulating the function of
TCTA protein in both small cell lung cancer and osteoclasts.
7. Conclusion
Aplan et al. demonstrated in 1995 that TCTA protein is as-
sociated with the tumorigenesis of ALL and small cell lung
cancer. The other functions of TCTA protein had not been
revealed until we demonstrated that the protein induces
human osteoclastogenesis in 2009. We are now investigating
the eﬀect of peptide A on the proliferation of cell lines of
human small lung cell cancer.Thus, a novel therapy forsmall
cell lung cancer with bone metastases may be developed
using peptide A from TCTA protein.
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